このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Biohit Oyj マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jussi Hahtela

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2yrs
CEOの所有権	0.3%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17

CEO（最高経営責任者

Jussi Hahtela (51 yo)

2yrs

在職期間

Mr. Jussi Hahtela serves as Chief Executive Officer of Biohit Oyj from September 02, 2022 and serves as its President. He served as Chief Financial Officer at Biohit Oyj since June 4, 2021. He is responsib...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Osmo Suovaniemi	Founder	36.7yrs	€14.00k	14.16% € 4.7m
Jussi Hahtela	President & CEO	2yrs	データなし	0.26% € 86.8k
Jussi Sorvo	Chief Financial Officer	2yrs	データなし	0.11% € 34.7k
Graham Johnson	Head of Global Sales & Marketing	less than a year	データなし	データなし
Yulia Kubacheva	Head of Diagnostics Department - Biohit Russia	18.3yrs	データなし	データなし
Ilari Patrakka	Chief Commercial Officer	less than a year	データなし	0.080% € 26.3k
Panu Hendolin	R&D Director	no data	データなし	0.087% € 28.6k

2.0yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: BIOBVの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Osmo Suovaniemi	Founder	36.7yrs	€14.00k	14.16% € 4.7m
Vesa-Pekka Silaskivi	Independent Chairman of the Board	1.3yrs	€8.00k	データなし
Mårten Wikström	Member of Scientific Advisory Board	no data	データなし	データなし
Pentti Sipponen	Scientific Advisor	no data	データなし	データなし
Seppo Sarna	Scientific Advisor	no data	データなし	データなし
Kalle Härkönen	Independent Director	2.3yrs	€14.00k	0.029% € 9.4k
Matti Harkonen	Scientific Advisor	no data	€3.00k	2.14% € 705.6k
Lea Paloheimo	Independent Director	5.4yrs	€14.00k	0.046% € 15.2k
Martti Marvola	Member of Scientific Advisory Board	no data	データなし	データなし
Feng Liu	Director	6.1yrs	€12.00k	データなし

5.4yrs

平均在職期間

73yo

平均年齢

経験豊富なボード: BIOBVの取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

Biohit Oyj マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Biohit Oyj Announces Changes in the Management Group

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Biohit Oyj Announces Executive Changes

No independent directors

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Recent updates

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 17% to €2.70

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Consensus EPS estimates increase by 18%

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: Revenues exceed analyst expectations

Biohit Oyj to Report First Half, 2024 Results on Aug 07, 2024

Biohit Oyj Announces Changes in the Management Group

New major risk - Earnings quality

First half 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Revises Earnings Guidance for 2023

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021)

Investor sentiment deteriorates as stock falls 19%

Biohit Oyj Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Biohit Oyj Announces Executive Changes

Biohit Oyj to Report Fiscal Year 2022 Final Results on Mar 22, 2023

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Biohit Oyj Appoints Panu Hendolin as Member of the Management Team

First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021)

Biohit Oyj Revises Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors

Biohit Oyj Elects Kalle Härkönen as Board of Director

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Biohit Oyj Provides Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Specifies Financial Guidance for 2021

Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection

First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020)

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

President & CEO Semi Korpela has left the company

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

New 90-day high: €2.26

Biohit Oyj to Report First Half, 2021 Results on Aug 11, 2021

Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.99

New 90-day low: €2.00

Biohit Oyj Elects Osmo Suovaniemi as the Chairman of the Board of Directors

New 90-day low - €2.14

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24